KNSA Stock Forecast & Price Target

Kiniksa Pharmaceuticals is favored because Arcalyst is showing strong commercial momentum, with 3Q Arcalyst revenue of $286 million, up 17.4% sequentially and 58.1% year over year, while FY26 revenue guidance was raised to $1.045-$1.050 billion. Its growth runway remains large given only 23% penetration of the ~14,000 multiple-recurrence RP population, over 5,450 prescribers, and increasing earlier-line use supported by ACC guidance, AI-driven targeting, and DTC traction. Fundamentally, the company is also highly attractive because it remains highly profitable, generating $54.2 million of operating income, $47.3 million of net income, and $568.8 million in cash and investments in 3Q26 while advancing KPL-387 as a potentially de-risked lifecycle extension with Phase 3 data expected in 2H27.

Kiniksa Pharmaceuticals is facing a negative outlook because its commercial trajectory depends heavily on weaker-than-expected adoption of Arcalyst in recurrent pericarditis, which raises concern that demand may not scale as expected. The company also faces meaningful competitive risk if better-than-expected rival products emerge, potentially undermining its ability to defend share and sustain momentum in its core rare-disease franchise. In addition, regulatory and commercial uncertainty around whether biologics for rare diseases can command premium pricing at commercialization adds pressure to valuation, especially given the company’s reliance on U.S. revenue.